ClinicalTrials.gg
RecruitingNCT07622563Updated Aug 5, 2026

Automated Oxygen Control in Preterms on Non-invasive Ventilation

An interventional study of Closed loop automated oxygen control in Infant, Premature and Airway Morbidity, sponsored by King's College Hospital NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 22 Weeks to 34 Weeks. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by King's College Hospital NHS Trust · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
22 Weeks to 34 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies in Premature Birth with a site in United Kingdom — 19 open to participants now, 25 under way, 1 of them phase 3. Premature Birth · United Kingdom.

Planned enrollment
22nd of 54
76 · median 58
Started
2026
with 2 others
No phase
38 of 100
7 open now
Primary completion
2027-06
later than 20 of 24 live
Registered
99th of 100
by date
Lead sponsor
5 of 100
King's College Hospital NHS Trust

Among the 100 studies in Premature Birth with a site in United Kingdom, this one is the 22nd largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 with no phase, reaches primary completion later than 20 of the 24 other live ones, and was the 99th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

19 of the 100 studies in Premature Birth with a site in United Kingdom are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 22 Weeks to 34 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Premature Birth with a site in United Kingdom, or all of them as a file.
02

Study summary

This randomised controlled trial aims to investigate the effectiveness of closed-loop automated oxygen control (CLAC) in preterm infants receiving non-invasive respiratory support and determine if it reduces the duration of supplementary oxygen treatment and improves achievement of oxygen saturation targets, reduces the incidences of hypoxia and hyperoxia, the number of manual adjustments to the inspired oxygen concentration (FiO2), and adverse outcomes including bronchopulmonary dysplasia (BPD).

The study will take place at King's College Hospital neonatal intensive care unit (NICU). Parents of preterm infants born at less than 34 weeks of gestation and receiving non-invasive respiratory support will be approached, informed and if appropriate consented to join the trial.

Participants will be randomised to receiving either automated or manual oxygen control.

The study will measure outcomes including the duration of supplementary oxygen treatment, the percentage of time spent within oxygen saturation targets, the incidences of hypoxia and hyperoxia, the number of manual FiO2 adjustments required, the overall duration of non-invasive respiratory support and length of neonatal unit stay, and the incidence of BPD at 36 weeks postmenstrual age (PMA). Results will be compared between the two groups.

Read the detailed description

Preterm infants frequently require supplemental oxygen to achieve adequate oxygen delivery to the tissues and allow for normal cell metabolism. Oxygen treatment, although life-saving, can further increase the risk of complications. Hyperoxia leads to the development of reactive oxide species (ROS) and increases oxidative stress for the neonates due to their immature antioxidant defence systems. Oxidative stress increases the risk of complications such as bronchopulmonary dysplasia and retinopathy of prematurity (ROP). On the other hand, hypoxia increases morbidity and mortality.

Studies have demonstrated that automated compared to manual oxygen control systems in preterm ventilated infants result in an improvement in the achievement of oxygen saturation targets, reduced time spent in hypoxia and hyperoxia and fewer manual adjustments to the inspired oxygen concentration. In addition, CLAC has been associated with earlier weaning of the inspired oxygen. In a RCT in preterm ventilated infants, CLAC was associated with shorter durations of mechanical ventilation (MV) and supplemental oxygen and reductions in the incidence of BPD and the proportion of infants discharged on home oxygen.

Preterm infants are increasingly managed on non-invasive respiratory support with an aim to minimise lung injury and reduce respiratory morbidity. Optimisation of supplemental oxygen treatment could further improve respiratory outcomes in this population. Previous studies on CLAC that included preterm infants on non invasive respiratory support showed promising results but they were of short duration. In addition, they did not report on the effect of CLAC on longer term outcomes. These limitations highlighted the need for an adequately powered randomised controlled trial (RCT) of CLAC versus manual oxygen control in preterm non-ventilated infants and for the whole duration of non-invasive respiratory support.

This study's hypothesis is that the use of CLAC in preterm infants \< 34 weeks of gestation receiving non-invasive respiratory support will reduce the duration of non-invasive ventilation (NIV). The investigators will also evaluate the time spent within oxygen saturation targets, the incidences of hypoxemia and hyperoxemia, the number of manual adjustments required by clinical staff, the total duration of supplemental oxygen treatment, the length of neonatal unit stay and the incidence of BPD at 36 weeks postmenstrual age (PMA).

This is a single centre, non-blinded, randomised controlled trial in preterm infants born at less than 34 weeks of gestation requiring non-invasive respiratory support at any postnatal age.

The investigators aim to recruit a minimum of 76 preterm infants (39 in each group) and over 12 months.

Informed written consent will be requested from the parents or legal guardians of the infants.

Eligible infants whose parents' consent to the study will be enrolled within 48 hours of initiation of non-invasive respiratory support. Infants who have not been eligible for recruitment within 48 hours of initiation of non-invasive support (for example outborn infants transferred to our unit at a later date) but who remain on it on day seven of life and beyond, they will be enrolled to the study immediately after obtaining parental consent and if less than fourteen days old.

Randomisation will be performed using an online randomisation generator. Patients will be receiving non-invasive support using SLE6000 ventilators or SLE6000N non-invasive respiratory device. Non-invasive support will include nasal continuous positive airway pressure (CPAP), non-invasive positive pressure ventilation (NIPPV) or humidified high flow nasal cannula oxygen (HHFNC). Settings will be manually adjusted by the clinical team as per unit's protocol. All participants will be connected to the standard bedside monitor (Philips IntelliVue MX750) that uses the Nellcor Neonatal SpO2 sensor. The intervention group, in addition to standard care will be also connected to the OxyGenie closed-loop oxygen saturation monitoring software (Inspiration Healthcare, Croydon, UK). Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.

The nurse-to-patient ratio will be according to the unit's protocol that is determined on the patient's acuity.

Patients will be studied from enrolment until weaning of non-invasive ventilation or 36 weeks PMA or discharge. If an infant is weaned to low flow nasal cannula oxygen or room air and subsequently requires resuming non-invasive ventilation, they will be studied in their initial arm if less than 36 weeks PMA. Therefore, for those infants randomised at the intervention group CLAC will resume. Preterm infants that remain on non-invasive respiratory support beyond 36 weeks PMA will continue at their study arm (CLAC or manual oxygen control) till their first weaning attempt.

03

Conditions studied

  • Infant
  • Premature
  • Airway Morbidity

Browse trials for

Keywords

  • automated oxygen control
  • non-invasive respiratory support
  • randomised controled trial
  • neonates
04

Who can participate

Ages eligible
22 Weeks to 34 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Preterm infants \<34 weeks of gestation and at any postnatal age on non-invasive respiratory support including:

  • non-invasive positive pressure ventilation (NIPPV)
  • nasal CPAP
  • HHFNC oxygen, either as primary or post extubation respiratory support.

Exclusion criteria

Exclusion Criteria:

  • Infants with congenital cyanotic heart disease.
  • Infants with other know major congenital abnormalities.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Automated oxygen control

    Automated oxygen titration

    Device: Closed loop automated oxygen control

  • No intervention
    Manual oxygen control

    Manual oxygen titration

Interventions

  • DeviceClosed loop automated oxygen control

    The OxyGenie closed-loop oxygen saturation monitoring software (Inspiration Healthcare) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.

06

What researchers measure

Primary outcomes

  1. The length of non-invasive ventilation

    Number of days participant receives non-invasive ventilation

    Time frame: Through study completion, up to 36 weeks post menstrual age

Secondary outcomes

  1. The change in the time spent within oxygen saturation targets

    Percentage of time with oxygen saturation levels between 91-95%.

    Time frame: Through study completion, up to 36 weeks post menstrual age

  2. The change in the time spent in hypoxia (SpO2<80%)

    Percentage of time with oxygen saturation levels below 80%

    Time frame: Through study completion, up to 36 weeks post menstrual age

  3. The change in the time spent in hyperoxia

    Percentage of time with oxygen saturation levels above 98%.

    Time frame: Through study completion, up to 36 weeks post menstrual age

  4. The change in the number of manual adjustments required

    Absolute difference in number of manual FiO2 adjustments

    Time frame: Through study completion, up to 36 weeks post menstrual age

  5. The change in the duration of supplemental oxygen treatment

    Number of days infants received supplemental oxygen

    Time frame: Through study completion, up to 36 weeks post menstrual age

  6. The change in the length of neonatal unit stay

    Number of days spent in neonatal unit

    Time frame: Through study completion, up to 36 weeks post menstrual age

  7. The change in the incidence of BPD at 36 weeks postmenstrual age

    The number of diagnosed cases of BPD among participants

    Time frame: Through study completion, up to 36 weeks post menstrual age

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Salverda HH, Cramer SJE, Witlox RSGM, Gale TJ, Dargaville PA, Pauws SC, Te Pas AB. Comparison of two devices for automated oxygen control in preterm infants: a randomised crossover trial. Arch Dis Child Fetal Neonatal Ed. 2022 Jan;107(1):20-25. doi: 10.1136/archdischild-2020-321387. Epub 2021 Jun 10. PubMed 34112721 ↗
  • Stafford IG, Lai NM, Tan K. Automated oxygen delivery for preterm infants with respiratory dysfunction. Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD013294. doi: 10.1002/14651858.CD013294.pub2. PubMed 38032241 ↗
  • Kaltsogianni O, Dassios T, Jenkinson A, Jeffreys E, Ikeda K, Sugino M, Greenough A. Closed-loop automated oxygen control in preterm ventilated infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2026 Apr 17;111(3):F243-F248. doi: 10.1136/archdischild-2025-329022. PubMed 41218846 ↗
  • Kaltsogianni O, Dassios T, Greenough A. Closed-Loop Automated Oxygen Control in Preterm Infants Receiving Non-Invasive Respiratory Support. Children (Basel). 2025 Nov 11;12(11):1528. doi: 10.3390/children12111528. PubMed 41300645 ↗
  • Claure N, Gerhardt T, Everett R, Musante G, Herrera C, Bancalari E. Closed-loop controlled inspired oxygen concentration for mechanically ventilated very low birth weight infants with frequent episodes of hypoxemia. Pediatrics. 2001 May;107(5):1120-4. doi: 10.1542/peds.107.5.1120. PubMed 11331696 ↗
  • Dani C. Automated control of inspired oxygen (FiO2 ) in preterm infants: Literature review. Pediatr Pulmonol. 2019 Mar;54(3):358-363. doi: 10.1002/ppul.24238. Epub 2019 Jan 10. PubMed 30632296 ↗
  • Saugstad OD, Aune D. In search of the optimal oxygen saturation for extremely low birth weight infants: a systematic review and meta-analysis. Neonatology. 2011;100(1):1-8. doi: 10.1159/000322001. Epub 2010 Dec 9. PubMed 21150224 ↗
  • Baba L, McGrath JM. Oxygen free radicals: effects in the newborn period. Adv Neonatal Care. 2008 Oct;8(5):256-64. doi: 10.1097/01.ANC.0000338015.25911.8a. PubMed 18827514 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 3, 2026
StartActual
Jun 12, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Sep 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07622563
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jun 12, 2026
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Ourania Kaltsogianni, MD (Res)
Contact
ourania.kaltsogianni@nhs.net
+44020 3299 9000 ext. 38493
Theodore Dassios, Professor
Contact
theodore.dassios@kcl.ac.uk
02032994644
Ourania Kaltsogianni
principal investigator · King's College Hospital NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion